tiprankstipranks
Trending News
More News >
Journey Medical Corp (DERM)
NASDAQ:DERM
US Market
Advertisement

Journey Medical Corp (DERM) AI Stock Analysis

Compare
102 Followers

Top Page

DERM

Journey Medical Corp

(NASDAQ:DERM)

Rating:56Neutral
Price Target:
$7.50
▲(6.23% Upside)
Journey Medical Corp's overall stock score is driven by financial challenges, including declining revenues and negative profitability, which are significant concerns. However, positive developments such as the successful launch of EMROSI, improved gross margins, and expanded payer access provide some optimism. Technical indicators are neutral, and the valuation remains unattractive due to ongoing losses. Recent corporate events are positive, enhancing the company's visibility and potential for growth.
Positive Factors
Market Positioning
DFD-29 is expected to be well-positioned to drive substantial long-term growth based on its superior data compared to Oracea.
Product Launch
The company expects a full commercial launch in early April, following the availability of the launch product and a national sales meeting.
Negative Factors
Stock Performance
Shares have traded down 14% since the product’s approval in November and are now valued at a 55% discount to peers on a 2026 EV/revenue basis.

Journey Medical Corp (DERM) vs. SPDR S&P 500 ETF (SPY)

Journey Medical Corp Business Overview & Revenue Model

Company DescriptionJourney Medical Corp (DERM) is a pharmaceutical company focused on the development and commercialization of dermatology treatments. The company aims to address unmet medical needs by providing innovative therapies for patients with skin disorders. Journey Medical's core products primarily consist of topical treatments and oral medications designed to treat a variety of dermatological conditions.
How the Company Makes MoneyJourney Medical Corp generates revenue primarily through the sale of its dermatological products. The company focuses on commercializing both proprietary and licensed products, leveraging its sales force and distribution channels to reach dermatologists and healthcare providers. Revenue streams are bolstered by strategic partnerships and licensing agreements with other pharmaceutical companies, allowing Journey Medical to expand its product offerings and market reach. Additionally, the company invests in research and development to enhance its product pipeline, which can lead to future revenue growth through the introduction of new and improved treatments.

Journey Medical Corp Earnings Call Summary

Earnings Call Date:Aug 12, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Nov 05, 2025
Earnings Call Sentiment Positive
The earnings call reflects a positive sentiment with the successful launch and strong performance of EMROSI, increased gross margins, and expanded payer access. However, these positive outcomes are slightly offset by declines in Accutane revenue, increased SG&A expenses, and a higher net loss.
Q2-2025 Updates
Positive Updates
Successful Launch of EMROSI
The second quarter of 2025 marks the first full quarter since the introduction of EMROSI, generating $2.8 million in sales and showing strong initial uptake with over 12,800 prescriptions.
Increase in Gross Margin
Gross margin increased to 67% for the second quarter of 2025 from 61% in the prior period, driven by product sales mix including EMROSI and Accutane.
Expanded Payer Access for EMROSI
Payer access for EMROSI increased from 30% of commercial lives in May to approximately 65% in July, covering over 100 million lives.
Recognition and Visibility
Journey Medical's stock was added to the small-cap Russell 2000 and broad market Russell 3000 indexes, and EMROSI was featured on Lifetime TV's The Balancing Act.
Negative Updates
Decline in Accutane Revenue
Accutane sales were pressured by aggressive pricing from generic competition, resulting in a $2.3 million decline compared to the prior year period.
Increased SG&A Expenses
SG&A expenses increased by $1.6 million to $11.9 million for the second quarter of 2025, primarily due to the launch and commercialization of EMROSI.
Net Loss Increase
Net loss to common shareholders was $3.8 million for the second quarter of 2025, compared to $3.4 million in the same period of 2024.
Company Guidance
During Journey Medical's second-quarter 2025 conference call, the company reported solid financial performance, driven by the successful launch of EMROSI, an oral rosacea treatment. Key metrics revealed that net product revenue reached $15 million, with EMROSI contributing approximately $2.8 million to this figure. Despite a decline in Accutane sales due to generic competition, the company’s gross margin improved to 67% from 61% in the prior year. The call highlighted that EMROSI prescriptions surpassed 12,800 by the end of July, achieving over 10% share of new prescription demand among dermatologists. Additionally, payer access for EMROSI expanded significantly, covering approximately 65% of commercial lives, up from 30% in May. Journey Medical maintained a stable cash position of $20.3 million, reflecting minimal cash burn for the year. The company expressed confidence in sustaining momentum, with plans to further expand prescriber base, increase prescription volume, and enhance profitability.

Journey Medical Corp Financial Statement Overview

Summary
Journey Medical Corp is facing financial challenges characterized by declining revenues, negative profitability margins, and worsening cash flow positions. While the company's debt levels have been managed effectively, operational inefficiencies and cash flow difficulties remain key areas of concern. The company needs to focus on revenue growth and cost optimization to improve overall financial health.
Income Statement
45
Neutral
The company experienced a significant decline in revenue from $79.2M to $56.1M over the past year, marking a revenue shrinkage of approximately 29.1%. The gross profit margin is stable as the gross profit equaled the total revenue. However, the net profit margin is negative due to persistent losses, with a net income of -$14.7M. EBIT and EBITDA margins are negative, highlighting operational inefficiencies and challenges in covering operating expenses with revenue.
Balance Sheet
55
Neutral
The debt-to-equity ratio decreased, reflecting better leverage management, with total debt significantly reduced from $17.7M to $201K. The equity ratio stands at 25%, indicating moderate financial stability. However, the company has faced a decline in stockholders' equity over the past year. The return on equity (ROE) remains negative, primarily due to continued net losses.
Cash Flow
50
Neutral
Operating cash flow turned negative at -$9.1M from a positive $5.2M last year, indicating cash flow challenges. The free cash flow also declined significantly, from $240K to -$9.1M. The operating cash flow to net income ratio is unfavorable due to negative figures. Despite these challenges, financing activities have provided a positive cash influx, improving liquidity.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue56.24M56.13M79.18M73.67M63.13M44.53M
Gross Profit37.39M35.26M52.52M42.89M31.05M29.94M
EBITDA-1.43M-8.40M1.92M-23.18M-32.77M9.37M
Net Income-8.30M-14.67M-3.85M-29.63M-43.99M5.28M
Balance Sheet
Total Assets84.96M80.24M76.85M105.16M97.28M51.91M
Cash, Cash Equivalents and Short-Term Investments21.07M20.30M27.44M32.00M49.08M8.25M
Total Debt25.17M25.70M17.73M22.96M9.05M5.40M
Total Liabilities63.42M60.17M56.50M88.18M55.24M41.61M
Stockholders Equity21.54M20.07M20.35M16.98M42.04M10.29M
Cash Flow
Free Cash Flow-6.94M-9.13M240.00K-33.53M-12.18M3.93M
Operating Cash Flow-6.94M-9.13M5.24M-13.53M-2.18M5.13M
Investing Cash Flow-15.00M-15.00M-5.00M-20.00M-10.00M-1.20M
Financing Cash Flow18.95M16.99M-4.80M16.46M53.02M-487.00K

Journey Medical Corp Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price7.06
Price Trends
50DMA
7.27
Negative
100DMA
7.13
Negative
200DMA
6.11
Positive
Market Momentum
MACD
-0.06
Positive
RSI
44.38
Neutral
STOCH
16.90
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DERM, the sentiment is Neutral. The current price of 7.06 is below the 20-day moving average (MA) of 7.30, below the 50-day MA of 7.27, and above the 200-day MA of 6.11, indicating a neutral trend. The MACD of -0.06 indicates Positive momentum. The RSI at 44.38 is Neutral, neither overbought nor oversold. The STOCH value of 16.90 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DERM.

Journey Medical Corp Risk Analysis

Journey Medical Corp disclosed 62 risk factors in its most recent earnings report. Journey Medical Corp reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Journey Medical Corp Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
60
Neutral
$467.76M23.44%-3.48%36.57%
56
Neutral
$185.75M-57.22%-27.40%-475.41%
53
Neutral
$54.75M-10.79%11.34%71.13%
51
Neutral
$7.92B-0.43-41.69%2.21%22.29%-1.85%
51
Neutral
$178.68M85.74-8.02%-22.98%-173.28%
50
Neutral
10.58%34.44%
33
Underperform
$168.85M-35.88%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
DERM
Journey Medical Corp
7.01
2.18
45.13%
IRWD
Ironwood Pharma
1.16
-2.82
-70.85%
ESPR
Esperion
2.68
0.98
57.65%
CPIX
Cumberland Pharmaceuticals
3.31
2.02
156.59%
OPTN
Optinose
9.60
-4.79
-33.29%
BIOA
BioAge Labs, Inc.
4.76
-16.24
-77.33%

Journey Medical Corp Corporate Events

Private Placements and FinancingBusiness Operations and Strategy
Journey Medical Corp Enters New Sales Agreement
Neutral
Aug 28, 2025

On August 28, 2025, Journey Medical Corporation entered into a new At Market Issuance Sales Agreement with B. Riley Securities, Inc. and Lake Street Capital Markets, LLC, allowing the company to sell up to 3,750,000 shares of its common stock. This agreement follows the termination of a previous sales agreement with B. Riley, under which the company sold 4,121,318 shares from December 30, 2022, to August 28, 2025. The new agreement, which includes customary terms and conditions, aims to provide Journey Medical with flexibility in raising capital, potentially impacting its financial strategy and market positioning.

Product-Related AnnouncementsBusiness Operations and Strategy
Journey Medical Expands Pharmacy Coverage for Emrosi
Positive
Jul 14, 2025

On July 14, 2025, Journey Medical Corporation announced an expansion in pharmacy benefit coverage for Emrosi™, a treatment for inflammatory lesions of rosacea in adults. The coverage increased from 29% to 65% of commercial lives in the United States, supporting the adoption of Emrosi as prescription demand rises. This expansion is expected to facilitate further growth in total prescription demand, positioning Emrosi as a potential standard of care for rosacea treatment.

Executive/Board ChangesShareholder Meetings
Journey Medical Corp Holds 2025 Annual Stockholders Meeting
Neutral
Jun 26, 2025

On June 24, 2025, Journey Medical Corporation held its 2025 Annual Meeting of Stockholders, where stockholders approved three key proposals. These included the election of six directors, the ratification of KPMG LLP as the independent registered public accounting firm for 2025, and the approval of the Fourth Amended and Restated Certificate of Incorporation, which includes provisions for officer exculpation.

Product-Related AnnouncementsDelistings and Listing Changes
Journey Medical Joins Russell 2000 and 3000 Indices
Positive
Jun 24, 2025

On June 24, 2025, Journey Medical Corporation announced its inclusion in the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 27, 2025. This inclusion is expected to increase the company’s visibility with investors and institutions, potentially impacting its market positioning positively. The company has also launched Emrosi™, an FDA-approved treatment for rosacea, which is off to a strong start, indicating a potentially transformational year for Journey Medical.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 30, 2025